Observation On The Effect Of The Same Dose Of RHuEPO Given One Time Or Two Times In The Treatment Of Renal Anemia

Research background Renal anemia caused mainly by renal tubular dysfunction, is a common clinical manifestation in patients with chronic renal failure. It causes reduction of erythropoietin,which is the direct reason for renal anemia. If renal anemia can not be corrected, renal function will become worser and worser. This theory is accepted by most nephrologists, extensive attention has been given to correct the renal anemia. Recombinant human erythropoietin is applied in the clinical for more than ten years. It has been proved by many clinical trials at home and abroad that the renal anemia and life quality of hemodialysis patients can be improved by recombinant human erythropoietin. It makes the patients with renal anemia receive effective treatment and avoid the drawbacks of blood transfusion. But rHuEPO is given many times a week, the pain of the patients is increased, so the compliance of patients is poor. Attention is paid by more and more clinical doctors that if the drug dose could be increased and the dose frequency could be decreased.Objective The effect of the same dose of rHuEPO given one time or two times in the treatment of renal anemia is observed.Research methods Patients with renal anemia was selected for observation and divided into the experimental group and control group.Both experimental group and control group included 25 cases. The experimental group was given erythropoien 10000IU one time a week, while the control group was given erythropoietin 5000IU two times a week.Both the experimental group and the control group was given by subcutaneous injection. The erythropoietin dose was adjused according to the Hb and Hct during the treatment. All subjects were followed up by 12 weeks. The symptoms and adverse reaction were recored. The Hb, Hct, and RBC that before treatment, week 4, week 8 and week 12 were recored.The electrolyte and hepatic function before and after the treatment were also recored. The effectiveness of the two groups was compared.Results The renal anemia is improved significantly after rHuEPO therapy. At week 12 the experimental group powerfully:10 patients (40.00%), effective:13 patients (52.00%), invalid:two patients (8.00%), the total effective rate was 92.00%. At week 12 the control group powerfully:9 patients (36.00%), effective:13 patients (52.00%), invalid:three patients (12.00%), the total effective rate was 88.00%. There is no significant difference between the experimental group and the control group (P≥0.05). There are no obvious changes in the electrolyte and hepatic function before and after the treatment.Conclusions It is also confirmed in this article that there is no significant difference in the treatment of renal anemia between erythropoietin 10000IU one time a week and 5000IU two times a week in the curative effect and adverse reactions. But the injection times are reduced and the compliance of the patients is improved.